20
Feb
2019

The Boston Cancer Summit and SF Cancer Summit. See the Agenda & Get Your Tickets

The Boston Cancer Summit is loaded with a stellar lineup of speakers on Apr. 16.

Same deal with the San Francisco Cancer Summit on Apr. 18.

I’m excited to announce the agendas for these special idea-and-networking forums. Hal Barron of GSK, David Schenkein of GV, Cindy Perettie of Foundation Medicine, and Ira Mellman of Genentech are a few of the outstanding speakers.

All proceeds — from tickets and sponsorships — will go directly to support cancer research at the Fred Hutchinson Cancer Research Center, a world leader. These Cancer Summits are part of the Kilimanjaro Climb to Fight Cancer. This is a philanthropic campaign mobilizing biotech executives and investors from around the country to raise $1 million for cancer research.

When you buy a ticket, you will be getting a superb learning opportunity, a rare networking opportunity, and an opportunity to support more terrific cancer biology to come at Fred Hutch.

Please take a look at the agendas below.

Thanks for your support of cancer research.

The Boston Cancer Summit, Apr. 16

Cancer R&D has never been more promising. Yet pricing and access to this new world of cancer therapy remains thorny. These issues have to be resolved if society is going to reap the benefits of this work. Come hear from some of the leading scientists, entrepreneurs, and investors about how they are thinking about the future. All ticket proceeds go to support basic science research at Fred Hutch.

REGISTER NOW: 1-6 pm, Apr. 16, Alexion Pharmaceuticals, 121 Seaport Blvd, Boston

AGENDA

1 pm Registration

1:30 pm Welcome Remarks. Alexion’s Deaidra Smith & Luke Timmerman

1:35 pm Why I’m Doing Kilimanjaro Climb to Fight Cancer (60 seconds each)

  • Uciane Scarlett, associate, Atlas Venture
  • Katrine Bosley, biotech entrepreneur
  • Praveen Tipirneni, CEO, Morphic Therapeutic

1:40 pm New Ideas for Cancer Treatment (10 minute slide presentations)

  • Simba Gill, Evelo Biosciences (monoclonal microbials for cancer)
  • Karen Akinsanya, chief biomedical scientist, Schrodinger
  • Sanjiv Patel, Relay Therapeutics, (computational drug discovery)
  • Art Krieg, Checkmate Pharmaceuticals (CpG oligonucleotides)
  • Tariq Kassum, Obsidian Therapeutics (tunable T-cell therapies)
  • Leigh Zawel, Cullinan Oncology (portfolio of platforms & mechanisms)

2:50 pm Cancer Investment Landscape. Separating the Hype from the Reality

  • Elliott Sigal, venture partner, NEA
  • Phil Rowlands, head, oncology therapeutic area unit, Takeda 
  • Doug Cole, managing partner, Flagship Pioneering (moderator)

3:20 pm BREAK

3:40 pm Where to Focus the Energy? A View From Pharma

  • Paul Biondi, SVP, business development and strategy, Bristol-Myers Squibb
  • John Reed, EVP, global head of R&D, Sanofi
  • Kate Haviland, Blueprint Medicines (moderator)

4 pm How to Make It Easier for Patients to Get Access to New Therapies?

  • Zoe Barry, CEO, ZappRx
  • Richa Wilson, Genentech/Roche, digital partnerships
  • Simon Kennedy, CEO, TriAxia Health (moderator)

4:30 pm What’s a Fair Way to Pay for All This?

  • Jeff Berkowitz, CEO, Real Endpoints
  • Leora Schiff, principal, Altius Strategy Consulting

5 pm Closing Conversation on the Future for Cancer Care

  • David Schenkein, executive chairman, Agios Pharmaceuticals; general partner GV
  • Mary Lynne Hedley, co-founder and president, Tesaro
  • Cindy Perettie, CEO, Foundation Medicine
  • Deb Palestrant, partner, 5AM Ventures (moderator)

5:30 pm A Word on the Kilimanjaro Climb to Fight Cancer.

  • Luke Timmerman

5:35 pm NETWORKING

6 pm END

Buy Tickets for Boston Cancer Summit

 

The San Francisco Cancer Summit, Apr. 18

Cancer R&D has never been more promising. Yet pricing and access to this new world of cancer therapy remains thorny. These issues have to be resolved if society is going to reap the benefits of this work. Come hear from some of the leading scientists, entrepreneurs, and investors about how they are thinking about the future. All ticket proceeds go to support basic science research at Fred Hutch.

REGISTER NOW: 1-6 pm, Apr. 18, Biocom Bay Area, 1 Tower Place, South San Francisco

AGENDA

1 pm Registration

1:30 pm Welcome. JLABS’ Lesley Stolz & Luke Timmerman

1:35 pm Why I’m Doing Kilimanjaro Climb to Fight Cancer (60 seconds each)

  • Lesley Stolz, head, JLABS Bay Area
  • Bill Newell, CEO, Sutro Biopharma
  • Ken Brunt, VP of customer operations, Veracyte
  • Julia Owens, CEO, Millendo Therapeutics

1:40 pm Why Genentech is Betting Big on Personalized T-cell therapies

  • Ira Mellman, vice president, research oncology, Genentech
  • Harlan Robins, member, Fred Hutch; program head, computational biology; co-founder, Adaptive Biotechnologies
  • Kristina Burow, managing director, ARCH Venture Partners (moderator)

2:00 pm New Ideas for Cancer (10 minutes each)

  • Carolyn Bertozzi, Anne T. and Robert M. Bass Professor of Chemistry at Stanford; Co-Founder, Palleon Pharmaceuticals (targeting glycan sensing checkpoints)
  • Omid Farokhzad, CEO, Seer (proteomics for early cancer detection)
  • Angie You, CEO, Amunix Pharmaceuticals (protein therapeutics)
  • Steve James, CEO, Pionyr Immunotherapeutics (antibodies for immune responses in tumor microenvironment)
  • Daniel Corey, founder and CSO, Cero Therapeutics (engineered T cells to engulf and degrade tumors)
  • Alex Franzusoff, CEO, PACT Pharma (neoantigen personalized cell therapy)
  • Ben Hindson, co-founder and CSO, 10X Genomics (insights from single-cell analysis)

3:10 pm The Future of Cancer Immunotherapy. T-cells, bispecifics, combo targeted therapies, all of the above?

  • David Chang, co-founder and CEO, Allogene Therapeutics
  • Bassil Dahiyat, CEO, Xencor
  • Stanley Riddell, member, Fred Hutch; scientific director, Immunotherapy Integrated Research Center; co-founder, Juno Therapeutics
  • Julia Owens, CEO, Millendo Therapeutics (moderator)

3:30 pm BREAK

3:50 pm Beyond the Science: Regulatory, Commercial and Data Transformations Enabling the Cancer Revolution

  • Amy DuRoss, CEO, Vineti
  • Kristen Hege, Corporate VP, translational development, hematology/oncology, Celgene
  • Nina Kjellson, general partner, Canaan Partners (moderator)

4:30 pm What Will it Take for Molecular Diagnostics Reach Their Potential?

  • Bonnie Anderson, co-founder and CEO, Veracyte
  • Kevin Conroy, CEO, Exact Sciences
  • Lesley Stolz, JLABS Bay Area (moderator)

5 pm Closing Conversation on the Future for Cancer Care

  • Hal Barron, chief scientific officer and president of R&D, GSK
  • Larry Corey, past president of Fred Hutch, co-PI, HIV Vaccine Trials Network; co-founder, Juno Therapeutics
  • Racquel Bracken, vice president, Venrock (moderator)

5:30 pm A Word on the Kilimanjaro Climb to Fight Cancer.

  • Luke Timmerman

5:35 pm NETWORKING

6 pm END

Buy Tickets for SF Cancer Summit

You may also like

Thank You, Biotech: Kili Climb to Fight Has Crushed Its $1m Goal for Cancer Research
Meet the Kilimanjaro Climb to Fight Cancer Team
Get Tickets Now: The Cancer Summit Series is Coming to Boston, SF, Seattle
First Everest, Now Kilimanjaro: Climb With Me and a Great Biotech Team to Fight Cancer